Home » AstraZeneca Settles Cancer Drug Patent Lawsuits With BMS, Ono for $510 Million
AstraZeneca Settles Cancer Drug Patent Lawsuits With BMS, Ono for $510 Million
AstraZeneca announced that it will pay $510 million to settle patent infringement lawsuits with Bristol Myers Squibb (BMS) and Ono Pharmaceutical involving cancer treatments using PD-1 and CTLA-4 methods.
Both BMS and Japanese drugmaker Ono Pharmaceutical had filed a series of lawsuits alleging that AstraZeneca’s marketing of Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) infringed on several of their patents.
BMS received $370 million in the settlement and Ono Pharmaceutical received $140 million.
See AstraZeneca’s Q2 report here.
To read the full story, click here to subscribe.
Related Topics
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May